Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared the risks of EHM and intrahepatic malignancy (IHM) between entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment. Methods: Using data from the National Health Insurance Service of Korea, this nationwide cohort study included treatment-naïve CHB patients who initiated ETV (n=24,287) or TDF (n=29,199) therapy between 2012 and 2014. The primary outcome was the development of any primary EHM. Secondary outcomes included overall IHM development. E-value was calculated to assess the robustness of results to unmeasured confounders. Results: The median follow-up duration was 5.9 years, and all baseline characteristics were well balanced after propensity score matching. EHM incidence rate differed significantly between within versus beyond 3 years in both groups (P<0.01, Davies test). During the first 3 years, EHM risk was comparable in the propensity scorematched cohort (5.88 versus 5.84/1,000 person-years; subdistribution hazard ratio [SHR]=1.01, 95% confidence interval [CI]=0.88–1.17, P=0.84). After year 3, however, TDF was associated with a significantly lower EHM incidence compared to ETV (4.92 versus 6.91/1,000 person-years; SHR=0.70, 95% CI=0.60–0.81, P<0.01; E-value for SHR=2.21). Regarding IHM, the superiority of TDF over ETV was maintained both within (17.58 versus 20.19/1,000 person-years; SHR=0.88, 95% CI=0.81–0.95, P<0.01) and after year 3 (11.45 versus 16.20/1,000 personyears; SHR=0.68, 95% CI=0.62–0.75, P<0.01; E-value for SHR=2.30). Conclusions: TDF was associated with approximately 30% lower risks of both EHM and IHM than ETV in CHB patients after 3 years of antiviral therapy.
Abstract
Background/Aims: Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared the risks of EHM and intrahepatic malignancy (IHM) between entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment. Methods: Using data from the National Health Insurance Service of Korea, this nationwide cohort study included treatment-naïve CHB patients who initiated ETV (n=24,287) or TDF (n=29,199) therapy between 2012 and 2014. The primary outcome was the development of any primary EHM. Secondary outcomes included overall IHM development. E-value was calculated to assess the robustness of results to unmeasured confounders. Results: The median follow-up duration was 5.9 years, and all baseline characteristics were well balanced after propensity score matching. EHM incidence rate differed significantly between within versus beyond 3 years in both groups (P<0.01, Davies test). During the first 3 years, EHM risk was comparable in the propensity scorematched cohort (5.88 versus 5.84/1,000 person-years; subdistribution hazard ratio [SHR]=1.01, 95% confidence interval [CI]=0.88–1.17, P=0.84). After year 3, however, TDF was associated with a significantly lower EHM incidence compared to ETV (4.92 versus 6.91/1,000 person-years; SHR=0.70, 95% CI=0.60–0.81, P<0.01; E-value for SHR=2.21). Regarding IHM, the superiority of TDF over ETV was maintained both within (17.58 versus 20.19/1,000 person-years; SHR=0.88, 95% CI=0.81–0.95, P<0.01) and after year 3 (11.45 versus 16.20/1,000 personyears; SHR=0.68, 95% CI=0.62–0.75, P<0.01; E-value for SHR=2.30). Conclusions: TDF was associated with approximately 30% lower risks of both EHM and IHM than ETV in CHB patients after 3 years of antiviral therapy.
참고문헌 (49)
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016 : a systematic analysis for the Global Burden of Disease Study 2016", Lancet, 390, pp.1211~1259 (2017)
- Lin CL, "Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection", Clin Mol Hepatol, 29, pp.605~622 (2023)
- European Association For The Study Of The Liver, "EASL 2017clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clin Mol Hepatol, 28, pp.276~331 (2022)
- Lee SW, "Entecavir versus tenofovir in patients with chronic hepatitis B : enemies or partners in the prevention of hepatocellular carcinoma", Clin Mol Hepatol, 27, pp.402~412 (2021)
- Choi J, "Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B : a Korean nationwide cohort study", JAMA Oncol, 5, pp.30~36 (2019)
- Yip TCF, "Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China", Gastroenterology, 158, pp.215~225 (2020)
- Dave S, "Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B : a systematic review and meta-analysis", Hepatology, 73, pp.68~78 (2021)
- Kim WR, "Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States", Aliment Pharmacol Ther, 55, pp.828~835 (2022)
- Kim SU, "A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea", J Hepatol, 71, pp.456~464 (2019)
- Tseng CH, "Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B : a systematic review and metaanalysis", Lancet Gastroenterol Hepatol, 5, pp.1039~1052 (2020)
- Oh H, "No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs tenofovir", Clin Gastroenterol Hepatol, 18, pp.2793~2802 (2020)
- Lee SW, "Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea : a large-scale, propensity score analysis", Gut, 69, pp.1301~1308 (2020)
- Papatheodoridis GV, "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B", J Hepatol, 73, pp.1037~1045 (2020)
- "NDA Review pharmacology/toxicology review and evaluation: NDA No. 21-797"[URL]
- Wong GLH, "ong-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk-a cohort study of 44494 subjects", Aliment Pharmacol Ther, 45, pp.1213~1224 (2017)
- Hou JL, "Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24countries", Clin Gastroenterol Hepatol, 18, pp.457~467 (2020)
- Lee DH, "Association of chronic hepatitis B infection and antiviral treatment with the development of the extrahepatic malignancies : a nationwide cohort study", J Clin Oncol, 40, pp.3394~3405 (2022)
- Seo HJ, "A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea", Asian Pac J Cancer Prev, 13, pp.6163~6168 (2012)
- VanderWeele TJ, "Sensitivity analysis in observational research : introducing the E-value", Ann Intern Med, 167, pp.268~274 (2017)
- Liu S, "Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy", J Infect Dis, 226, pp.881~890 (2022)
- Lim YS, "New biomarkers of hepatitis B virus (HBV) infection:HBV RNA and HBV core-related antigen, new kids on the block?", Clin Mol Hepatol, 29, pp.118~119 (2023)
- Woo G, "Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B : a systematic review and Bayesian meta-analyses", Gastroenterology, 139, pp.1218~1229 (2010)
- Zuo SR, "A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection", J Clin Pharmacol, 55, pp.288~297 (2015)
- Chen MB, "Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B : a systematic review and meta-analysis", PLoS One, 14, pp.e0224773~ (2019)
- Gao L, "Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAgpositive chronic hepatitis B patients with high HBV DNA", Aliment Pharmacol Ther, 39, pp.629~637 (2014)
- Kamiza AB, "Chronic hepatitis infection is associated with extrahepatic cancer development : a nationwide population-based study in Taiwan", BMC Cancer, 16, pp.861~ (2016)
- Song C, "Associations between hepatitis B virus infection and risk of all cancer types", JAMA Netw Open, 2, pp.e195718~ (2019)
- Hur MH, "The imitator of immune-tolerant chronic hepatitis B : a killer in disguise", Clin Mol Hepatol, 29, pp.363~366 (2023)
- Chen NL, "Expression of hepatitis B virus antigen and Helicobacter pylori infection in gastric mucosa of patients with chronic liver disease", Hepatobiliary Pancreat Dis Int, 3, pp.223~225 (2004)
- Lai KN, "Detection of hepatitis B virus DNA and RNA in kidneys of HBV related glomerulonephritis", Kidney Int, 50, pp.1965~1977 (1996)
- Murata K, "Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues : a new potential target for HBV infection", Gut, 67, pp.362~371 (2018)
- Abushahba W, "Antitumor activity of type I and type III interferons in BNL hepatoma model", Cancer Immunol Immunother, 59, pp.1059~1071 (2010)
- Sato A, "Antitumor activity of IFN-λ in murine tumor models", J Immunol, 176, pp.7686~7694 (2006)
- Lim SH, "Prevalence and risk factors of Helicobacter pylori infection in Korea : nationwide multicenter study over 13 years", BMC Gastroenterol, 13, pp.104~ (2013)
- Thandra KC, "Epidemiology of non-Hodgkin’s lymphoma", Med Sci(Basel), 9, pp.5~ (2021)
- Skibola CF, "Obesity, diet and risk of non-Hodgkin lymphoma", Cancer Epidemiol Biomarkers Prev, 16, pp.392~395 (2007)
- Vaccarella S, "Challenges in investigating risk factors for thyroid cancer", Lancet Diabetes Endocrinol, 9, pp.57~59 (2021)
- Rockey DC, "Liver fibrosis reversion after suppression of hepatitis B virus", Clin Liver Dis, 20, pp.667~679 (2016)
- Papatheodoridis GV, "The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B", Hepatology, 66, pp.1444~1453 (2017)
- Brown JA, "Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases", Chem Res Toxicol, 25, pp.225~233 (2012)
- Jiang L, "Genetic evidence for genotoxic effect of entecavir, an anti-hepatitis B virus nucleotide analog", PLoS One, 11, pp.e0147440~ (2016)
- Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
- Su TH, "Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients", Liver Int, 36, pp.1755~1764 (2016)
- Kim J, "Inverse propensity score-weighted analysis of entecavir and tenofovir disoproxil fumarate in patients with chronic hepatitis B : a large-scale multicenter study", Cancers(Basel), 15, pp.2936~ (2023)
- Hur MH, "Personalized antiviral drug selection in patients with chronic hepatitis B using a machine learning model : a multinational study", Am J Gastroenterol, 118, pp.1963~1972 (2023)
- Song BC, "Hepatitis B virus genotypes in Korea : an endemic area of hepatitis B virus infection", Intervirology, 48, pp.133~137 (2005)
- Kim BK, "HBV genotypes : relevance to natural history, pathogenesis and treatment of chronic hepatitis B", Antivir Ther, 16, pp.1169~1186 (2011)